Authors’ conclusion: to vaccinate children up to 24 months of life, previously immunized with 7-valent pneumococcal conjugate vaccine, in a catch-up programme, with a catch-up 13-valent vaccine is justified from an economic point of view. The average cost per event avoided is 1674 Euros vaccinating children up to 24 months, and increases to 2522 Euros by vaccinating up to 60 months of age. The cost per year of life saved for different vaccination strategies is always acceptable (from 12,250 Euros to 22,093 Euros).
Reviewers’ commentary: if the cost-effectiveness estimates were similar in our sanitary system, a catch-up campaign with a 13-valent vaccine would be an intervention to consider, although, given its high price, in competition with others of similar cost-utility. However, it is needed to know the impact of changes in some assumptions of effectiveness, of which there is no direct evidence, which could have biased the cost-utility estimates.